Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective (2020)
Ulrich, Henning 
; Pillat, Micheli Mainardi ; Tárnok, Attila
Fonte: Cytometry Part A. Unidade: IQ
Assuntos: DENGUE, CORONAVIRUS, ANTICORPOS, COVID-19
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ULRICH, Henning e PILLAT, Micheli Mainardi e TÁRNOK, Attila. Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective. Cytometry Part A, v. 97A, p. 662–667, 2020Tradução . . Disponível em: https://doi.org/10.1002/cyto.a.24047. Acesso em: 15 nov. 2024.APA
Ulrich, H., Pillat, M. M., & Tárnok, A. (2020). Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective. Cytometry Part A, 97A, 662–667. doi:10.1002/cyto.a.24047NLM
Ulrich H, Pillat MM, Tárnok A. Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective [Internet]. Cytometry Part A. 2020 ; 97A 662–667.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1002/cyto.a.24047Vancouver
Ulrich H, Pillat MM, Tárnok A. Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective [Internet]. Cytometry Part A. 2020 ; 97A 662–667.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1002/cyto.a.24047
